Latest Breaking News On - நிமிடம் நட சோதனை - Page 1 : comparemela.com
Solid Biosciences Reports 1 5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Nexviazyme Approved for Late-Onset Pompe Disease
empr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from empr.com Daily Mail and Mail on Sunday newspapers.
COVID-19 India Update: Delhi s daily Covid cases witnessed a slight rise on day three of unlocking
Highlights
The Covid recovery rate has improved to 94.77%
The positivity rate stood at 4.69%, below 5% for the 3rd day
New Delhi: India reported 94,052 new COVID-19 cases and 6,148 new deaths today. The country has so far reported a total of 2,91,83,121 cases and 3,59,676 deaths.
Here are the top 10 updates on coronavirus in India:
India s test positivity rate (positive cases identified for every 100 tests) continues to decline. It stands at 4.69 per cent, the third straight day that it is below the 5 per cent-mark.
Tamil Nadu reported 17,321 infections, followed by Kerala (16,204) Maharashtra (10,989) and Karnataka (10,959).
The guidelines also said Remdesivir (an emergency use authorization drug) is not recommended in children.
There is lack of sufficient safety and efficacy data with respect to Remdesivir in children below 18 years of age, the guidelines said.
The guidelines suggested rational use of High-resolution CT (HRCT) for seeing the extent and nature of lung involvement in patients with COVID-19.
However, any additional information gained from HRCT scan of the chest often has little impact on treatment decisions, which are based almost entirely on clinical severity and physiological impairment. Therefore, treating physicians should be highly selective in ordering HRCT imaging of the chest in COVID-19 patients, the guidelines said.
vimarsana © 2020. All Rights Reserved.